Repurposing levocetirizine hydrochloride loaded into cationic ceramide/phospholipid composite (CCPCs) for management of alopecia: central composite design optimization, in- silico and in-vivo studies
Authors:
Open Access
- 1 September 2022
- journal article
- research article
- Published by Taylor & Francis in Drug Delivery
- Vol. 29 (1) , 2784-2795
Abstract
Levocetirizine hydrochloride (LVC) is an antihistaminic drug that is repurposed for the treatment of alopecia. This investigation is targeted for formulating LVC into cationic ceramide/phospholipid composite (CCPCs) for the management of alopecia. CCPCs were fabricated by ethanol-injection approach, through a central composite experiment. CCPCs were evaluated by inspecting their entrapment efficiency (EE%), polydispersity index (PDI), particle size (PS), and zeta potential (ZP). The optimum CCPCs were additionally studied by in-vitro, ex-vivo, in-silico, and in-vivo studies. The fabricated CCPCs had acceptable EE%, PS, PDI, and ZP values. The statistical optimization elected optimum CCPCs composed of 5 mg hyaluronic acid, 10 mg ceramide III, and 5 mg dimethyldidodecylammonium bromide employing phytantriol as a permeation enhancer. The optimum CCPCs had EE%, PS, PDI, and ZP of 88.36 ± 0.34%, 479.00 ± 50.34 nm, 0.377 ± 0.0035, and 20.20 ± 1.13 mV, respectively. The optimum CCPC maintained its stability for up to 90 days. It also viewed vesicles of tube shape via transmission electron microscope. The in-silico assessment resulted in better interaction and stability between LVC and vesicle components in water. The ex-vivo and in-vivo assessments showed satisfactory skin retention of LVC from optimum CCPCs. The histopathological assessment verified the safety of optimum CCPCs to be topically applied. Overall, the optimum CCPCs could be utilized as a potential system for the topical management of alopecia, with a prolonged period of activity, coupled with reduced LVC shortcomings.Keywords
Funding Information
- Deanship of Scientific Research (DSR) at King Abdulaziz University (KAU), Jeddah, Saudi Arabia
This publication has 42 references indexed in Scilit:
- Hyaluronic acid-coated solid lipid nanoparticles for targeted delivery of vorinostat to CD44 overexpressing cancer cellsCarbohydrate Polymers, 2014
- Ceramide: A simple sphingolipid with unique biophysical propertiesProgress in Lipid Research, 2014
- Novel flexible vesicles based topical formulation of levocetirizine:in vivoevaluation using oxazolone-induced atopic dermatitis in murine modelJournal of Liposome Research, 2014
- Formulation by design-based proniosome for accentuated transdermal delivery of risperidone:in vitrocharacterization andin vivopharmacokinetic studyDrug Delivery, 2014
- Androgenetic alopecia as an early marker of benign prostatic hyperplasiaJournal of the American Academy of Dermatology, 2012
- Retained topical delivery of 5-aminolevulinic acid using cationic ultradeformable liposomes for photodynamic therapyEuropean Journal of Pharmaceutical Sciences, 2011
- Alopecia areata: Clinical presentation, diagnosis, and unusual casesDermatologic Therapy, 2011
- Simultaneous quantification of cefpirome and cetirizine or levocetirizine in pharmaceutical formulations and human plasma by RP-HPLCJournal of Analytical Chemistry, 2008
- Effect of Solid Lipid Nanoparticles Formulation Compositions on Their Size, Zeta Potential and Potential for In Vitro pHIS-HIV-Hugag TransfectionPharmaceutical Research, 2007
- Alopecia areata updateJournal of the American Academy of Dermatology, 2000